MA40363A - Agents de liaison de rspo1 et leurs utilisations - Google Patents
Agents de liaison de rspo1 et leurs utilisationsInfo
- Publication number
- MA40363A MA40363A MA040363A MA40363A MA40363A MA 40363 A MA40363 A MA 40363A MA 040363 A MA040363 A MA 040363A MA 40363 A MA40363 A MA 40363A MA 40363 A MA40363 A MA 40363A
- Authority
- MA
- Morocco
- Prior art keywords
- binding agents
- rspo1 binding
- rspo1
- rspo
- administering
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne des agents de liaison de rspo, en particulier des anticorps qui se lient spécifiquement au rspol humain. L'invention concerne également des procédés de traitement de cancer et d'autres maladies, consistant à administrer une quantité thérapeutiquement efficace d'un agent ou d'un anticorps de la présente invention à un patient en ayant besoin.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462037880P | 2014-08-15 | 2014-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA40363A true MA40363A (fr) | 2017-06-21 |
Family
ID=55304654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA040363A MA40363A (fr) | 2014-08-15 | 2015-08-14 | Agents de liaison de rspo1 et leurs utilisations |
Country Status (9)
Country | Link |
---|---|
US (1) | US20170247437A1 (fr) |
EP (1) | EP3180027A4 (fr) |
JP (1) | JP2017526356A (fr) |
CN (1) | CN106714833A (fr) |
AU (1) | AU2015301538A1 (fr) |
CA (1) | CA2958144A1 (fr) |
MA (1) | MA40363A (fr) |
MX (1) | MX2017001983A (fr) |
WO (1) | WO2016025797A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109529040B (zh) * | 2017-09-21 | 2020-11-13 | 华东师范大学 | LGR4和R-spondin结合抑制剂及其在肿瘤治疗中的用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006031825A2 (fr) * | 2004-09-13 | 2006-03-23 | Macrogenics, Inc. | Anticorps humanises contre le virus du nil occidental ainsi qu'utilisations therapeutiques et prophylactiques associees |
WO2006067122A2 (fr) * | 2004-12-20 | 2006-06-29 | Crucell Holland B.V. | Molecules de liaison capables de neutraliser le virus du nil occidental et utilisations correspondantes |
DE602007011923D1 (de) * | 2006-06-02 | 2011-02-24 | Aveo Pharmaceuticals Inc | Hepatocytenwachstumsfaktor-(hgf-)bindungsproteine |
AR061170A1 (es) * | 2006-06-02 | 2008-08-06 | Aveo Pharmaceuticals Inc | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) |
JP2010531137A (ja) * | 2007-06-12 | 2010-09-24 | ワイス・エルエルシー | 抗cd20治療用組成物および方法 |
EP2313435A4 (fr) * | 2008-07-01 | 2012-08-08 | Aveo Pharmaceuticals Inc | Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3) |
NZ592338A (en) * | 2008-09-26 | 2012-11-30 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
CN102395597A (zh) * | 2009-03-11 | 2012-03-28 | 惠氏有限责任公司 | 纯化小模块免疫药物蛋白的方法 |
AU2010263058A1 (en) * | 2009-06-18 | 2012-01-12 | Wyeth Llc | Lyophilized formulations for small modular immunopharmaceuticals |
RU2595409C2 (ru) * | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
WO2011085289A1 (fr) * | 2010-01-11 | 2011-07-14 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Production d'un anticorps monoclonal thérapeutique contre le virus west nile chez les plantes |
CN106167526A (zh) * | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | Rspo结合剂和其应用 |
-
2015
- 2015-08-14 US US15/503,928 patent/US20170247437A1/en not_active Abandoned
- 2015-08-14 WO PCT/US2015/045210 patent/WO2016025797A1/fr active Application Filing
- 2015-08-14 JP JP2017508493A patent/JP2017526356A/ja active Pending
- 2015-08-14 EP EP15832300.6A patent/EP3180027A4/fr not_active Withdrawn
- 2015-08-14 CN CN201580049379.8A patent/CN106714833A/zh active Pending
- 2015-08-14 AU AU2015301538A patent/AU2015301538A1/en not_active Abandoned
- 2015-08-14 CA CA2958144A patent/CA2958144A1/fr active Pending
- 2015-08-14 MA MA040363A patent/MA40363A/fr unknown
- 2015-08-14 MX MX2017001983A patent/MX2017001983A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2015301538A1 (en) | 2017-03-02 |
WO2016025797A1 (fr) | 2016-02-18 |
WO2016025797A4 (fr) | 2016-03-31 |
US20170247437A1 (en) | 2017-08-31 |
EP3180027A1 (fr) | 2017-06-21 |
MX2017001983A (es) | 2017-05-23 |
CA2958144A1 (fr) | 2016-02-18 |
JP2017526356A (ja) | 2017-09-14 |
EP3180027A4 (fr) | 2018-01-10 |
CN106714833A (zh) | 2017-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
MX2020001513A (es) | Agentes de union a clec9a y su uso. | |
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
NZ738008A (en) | Tigit-binding agents and uses thereof | |
PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
MX2020011772A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2017004526A (es) | Terapia combinada de anticuerpos biespecificos especificos para fap y dr5 y agentes quimioterapeuticos. | |
NZ707086A (en) | Anti-cd40 antibodies and methods of use | |
GEP20217317B (en) | Combination therapy for the treatment of cancer | |
MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
MX2022000242A (es) | Anticuerpos contra ticagrelor y metodos de uso. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
MA40363A (fr) | Agents de liaison de rspo1 et leurs utilisations | |
MX2022000317A (es) | Anticuerpos altamente potentes que se unen al receptor de muerte 4 y al receptor de muerte 5. | |
MX2018004228A (es) | Anticuerpo que se une especificamente a erbb3 y uso de este. |